Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma

Leuk Lymphoma. 2023 Sep;64(9):1579-1582. doi: 10.1080/10428194.2023.2223743. Epub 2023 Jun 21.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Humans
  • Lymphoma, Mantle-Cell* / drug therapy
  • Lymphoma, Mantle-Cell* / pathology
  • Neoplasm Recurrence, Local / drug therapy

Substances

  • ublituximab
  • umbralisib
  • venetoclax